Popular Articles
Stretch Mark

Promising Results With Aleglitazar, A New Treatment Drug For Type 2 Diabetes (SYNCHRONY Study)
The results from the phase II SYNCHRONY study are published in an article Online First and in a future edition of The Lancet. At the same time, the findings are presented at the American Diabetes Association meeting in New Orleans, USA. They suggest that aleglitazar, a treatment for type 2 diabetes, might be safe and effective and may perhaps be introduced into phase III trials.
generic viagra online
Boehringer Ingelheim To Commence Phase III Study Investigating BIBW 2992 As Treatment For Non-Small Cell Lung Cancer Patients With EGFR Mutations
Boehringer Ingelheim announced today at the International Association for the Study of Lung Cancer"s 13th World Conference on Lung Cancer (WCLC), San Francisco, CA, the initiation of a Phase III clinical study of BIBW 2992 as first-line treatment in non-small cell lung cancer (NSCLC) patients with epidermal growth factor receptor (EGFR) mutations. BIBW 2992 (planned brand name Tovok™) is the first orally-administered, irreversible dual inhibitor of EGFR and HER2,1 to reach Phase III development in NSCLC.2
News of the day
MiR-196a Promotes The Metastases Of Tumors
MicroRNAs are small RNA molecules of 20-25 nucleotides length, regulating gene expression by inhibition of transcription or translation of proteins. High levels of miR-196a, a microRNA suppressing the expression of specific homebox genes that are of high relevance for the development of the human embryo, activated oncogenic pathways inside human tumor cells and induced tumor cell dissemination. miR-196a increased the chemosensitivity towards platin derivatives such as cisplatin and oxaliplatin and might be a useful biomarker.
Nutrition

New Research At University Of Leicester Offers Hope For Heart And Cancer Treatments

Researchers in the Department of Cardiovascular Sciences at the University of Leicester are developing a new way to make protein based drugs with potential applications in stroke, vascular inflammation, blood vessel formation, regenerative medicine and tissue engineering. The research carried out by Shikha Sharma in Dr Nick Brindle"s group in Department of Cardiovascular Sciences aims to allow researchers to rapidly make "designer proteins" that can bind to disease causing molecules in the body. Shikha Sharma said "There are millions of different proteins that are involved in carrying out numerous functions in the human body. Over time each protein has evolved to optimise its function. Disease could result if any of these fail to perform efficiently." "By generating designer proteins in test tubes, we can produce molecules that have specific actions to control processes in the body. These proteins can be used to make drugs as a treatment for heart disease and cancer." She said: "Whilst most drugs in current use are synthetic, these designer molecules are developed from natural proteins and are likely to have fewer side effects. Proteins perform a well defined but complex set of function in the body and protein therapeutic drugs can perform better when compared to some synthetic small molecule drugs that may have unwanted interactions within the body." "Current methods to generate protein therapeutic are cumbersome and time consuming. At the University of Leicester, we have developed a novel method to revolutionise the way in which we produce these designer protein drugs. In principle this method mimics natural evolution to make new proteins but over a shorter timescale. Instead of taking millions of years, we can create new proteins in just a few weeks." She said: "The fact that this new method utilizes a similar mechanism by which antibodies are generated, suggests the output from this method will be as robust and dynamic as the wide range of antibodies produced in our bodies to fight the rapidly evolving viruses in the environment." Dr Brindle said: "Shikha has made great progress towards this new method, which holds the promise of new better drugs for a wide range of human and animal disease." In addition to medicine, the method holds promise for a wide range of applications in the chemical, pharmaceutical, and agricultural industries, such as generating protein molecules to prevent uptake of toxins in crops or protein molecules for detection of environmental pollutants. Shikha Sharma will be presenting her research at the Festival of Postgraduate Research which is taking place on Thursday 25th June in the Belvoir Suite, Charles Wilson Building, University of Leicester between 11.30am and 1pm. This event is open to the public and is FREE to attend. Shikha Sharma University of Leicester


Add your comment:
Name:
Site address: http://
Your message:
Enter today\\\\'s date, 2 digits
(spam protection):